Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 4/20 | 0.36 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.34 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.34 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.34 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.34 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.34 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.33 |
| ▸ | EDNRA | P25101 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL502046 | 0.86 | SCN9A (0.33) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL502331 | 0.82 | SCN9A (0.36) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL3329045 | 0.78 | SCN9A (0.43) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL280762 | 0.73 | SCN9A (0.42) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL3337223 | 0.71 | SCN9A (0.53) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL280936 | 0.71 | SCN9A (0.53) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL3331005 | 0.71 | SCN9A (0.53) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL281648 | 0.69 | SCN9A (0.53) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL17169515 | 0.67 | SCN9A (0.55) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL2305420 | 0.67 | SCN9A (0.40) | SCN9ASCN7ASCN5ASCN2ASCN8A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106087-B2 | Spiro-oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2012-01-31 | — | — | US | disclosed |
| US-20100125072-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2010-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125072-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | OPRK1, OPRD1, SCN3A | SCN9A 47/4885SCN7A 79/4885SCN5A 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.